» Articles » PMID: 38632216

Evaluation of the Relation Between Subclinical Systolic Dysfunction Defined by Four-dimensional Speckle-tracking Echocardiography and Growth Differentiation Factor-15 Levels in Patients with Acromegaly

Overview
Specialty Endocrinology
Date 2024 Apr 17
PMID 38632216
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: In patients with acromegaly, the long-term presence of elevated GH and IGF-1 levels is associated with an unfavorable cardiovascular risk profile. We aimed to assess the relationship of four-dimensional speckle tracking echocardiographic (4DSTE) measurements with growth differentiation factor-15 (GDF-15) levels and the Framingham Cardiovascular Risk Score (FRS) in patients with acromegaly.

Methods: A single-center, cross-sectional study was conducted. The study included 40 acromegaly and 32 age- and gender-matched controls. Anthropometric, biochemical, and echocardiographic assessments were performed. GDF-15 levels were measured using ELISA.

Results: In the controlled acromegaly group, global longitudinal (GLS), circumferential (GCS), area (GAS), and radial (GRS) strain measurements identified by 4DSTE were lower than those of the controls (p < 0.05). Moreover, strain parameters were lower in active acromegaly patients than in controls, but the difference was not statistically significant. The GLS was negatively correlated with age, the estimated disease duration, and FRS. Serum GDF-15 levels showed no significant difference between the acromegaly and control groups. In patients with acromegaly, serum GDF-15 levels were positively correlated with age, waist-to-hip ratio, systolic and diastolic blood pressure, FRS, fasting plasma glucose, and HbA1c, but not with strain parameters. The multiple regression analysis revealed that FRS was an independent factor associated with serum GDF-15 levels in patients with acromegaly and the overall cohort (p < 0.001).

Conclusion: Our study demonstrates that while LVEF was within normal limits, global strain parameters (GLS, GCS, GAS, and GRS) measured by using a novel imaging technique, 4DSTE, were lower in patients with acromegaly, suggesting the presence of subclinical systolic dysfunction in patients with acromegaly. GDF-15 can be a potential predictor of cardiovascular risk in patients with acromegaly.

Citing Articles

Myocardial Mechanics in Acromegaly: A Meta-Analysis of Echocardiographic Studies.

Gherbesi E, Faggiano A, Sala C, Carugo S, Grassi G, Cuspidi C High Blood Press Cardiovasc Prev. 2024; 31(5):451-459.

PMID: 39242463 DOI: 10.1007/s40292-024-00667-9.

References
1.
Hong S, Kim K, Han K, Park C . Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J. 2021; 43(15):1491-1499. DOI: 10.1093/eurheartj/ehab822. View

2.
Akgul E, Tokgozoglu S, Erbas T, Kabakci G, Aytemir K, Haznedaroglu I . Evaluation of the impact of treatment on endothelial function and cardiac performance in acromegaly. Echocardiography. 2010; 27(8):990-6. DOI: 10.1111/j.1540-8175.2010.01179.x. View

3.
Sendur S, Hazirolan T, Aydin B, Lay I, Alikasifoglu M, Erbas T . Specific FSTL1 polymorphism may determine the risk of cardiomyopathy in patients with acromegaly. Acta Cardiol. 2021; 77(4):350-359. DOI: 10.1080/00015385.2021.1948206. View

4.
Chiloiro S, Giampietro A, Gagliardi I, Bondanelli M, Veleno M, Ambrosio M . Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary. 2022; 25(6):831-841. PMC: 9362053. DOI: 10.1007/s11102-022-01266-4. View

5.
Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J . The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006; 98(3):351-60. DOI: 10.1161/01.RES.0000202805.73038.48. View